Alvotech was left reeling last month after being denied US approval for its AVT02 proposed high-concentration biosimilar to Humira (adalimumab), with the clock ticking on its prospective 1 July allowed entry date into the market.
The US Food and Drug Administration blocked approval for the biosimilar by issuing a complete response letter over deficiencies at...






